Whitfield Dianne C. 4

What Happened

• Dianne C. Whitfield, Chief Human Resources Officer of Tarsus Pharmaceuticals (TARS), was granted equity awards on 2026-03-05. The Form 4 reports a derivative award of 27,310 option shares (acquired at $0.00) and 17,161 Restricted Stock Units (RSUs) (acquired at $0.00). These are compensation awards (transaction code A), not open-market purchases or sales.

Key Details

• Transaction date: 2026-03-05; Form 4 filed: 2026-03-09 (filed within the standard 2 business-day window).
• Option grant: 27,310 derivative shares (price reported $0.00). Vesting: 25% vests on March 5, 2027, then 1/48th of the option shares vests each month thereafter for 3 years, subject to continuous service (Footnote F1).
• RSU grant: 17,161 RSUs (each RSU = right to one share) with vesting in four equal annual installments on March 15 of 2027, 2028, 2029 and 2030, subject to continuous service (Footnotes F2, F3).
• Shares owned after the transaction: not disclosed in the provided filing.
• These awards were granted (A) as compensation; no immediate cash paid or share sales were reported.

Context

• RSUs convert to common stock only upon vesting, so they do not represent immediate share ownership. The option award is a derivative that vests over time and is exercisable per its grant terms; the filing does not indicate a cashless exercise or sale of shares. Such compensation grants are common for executive retention and do not by themselves signal immediate buying or selling of stock.